Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

ANNOUNCEMENT
BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING

The board (the "**Board**") of directors (the "**Directors**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**") hereby announces that the extraordinary general meeting of the Company (the "**EGM**") will be held at the Company's conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province, the People's Republic of China at 10:00 a.m. on Thursday, February 12, 2026.

For the purpose of determining the entitlements of the shareholders of the Company (the "**Shareholders**") to attend and vote at the EGM, the register of members of the Company will be closed from February 9, 2026 to February 12, 2026, both days inclusive, during which period no transfer of shares of the Company will be registered. In order to qualify to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H shares registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on February 6, 2026.

The Company will dispatch the circular and notice of the EGM, as well as the related form of proxy to the Shareholders in due course.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, January 26, 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.